• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antithrombotic therapy in patients with combined coronary heart disease and atrial fibrillation.
CONCLUSION: In each clinical scenario, the risks of coronary artery or stent thrombosis in CHD and risks of stroke in AF need to be carefully balanced against the risks of bleeding. We make recommendations for management based on the evidence which is available at this time and indicate the many gaps which are currently being addressed by randomised clinical trials. PMID: 26658287 [PubMed - as supplied by publisher]
Source: Panminerva Medica - December 15, 2015 Category: Journals (General) Tags: Panminerva Med Source Type: research

Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study Coronary Heart Disease
Conclusions In community practice, prasugrel use may be driven more by bleeding risk rather than ischemic benefit. This may result in underutilization of higher potency ADP receptor inhibitor among patients more likely to derive ischemic benefit.
Source: JAHA:Journal of the American Heart Association - September 22, 2016 Category: Cardiology Authors: Vora, A. N., Peterson, E. D., McCoy, L. A., Effron, M. B., Anstrom, K. J., Faries, D. E., Zettler, M. E., Fonarow, G. C., Baker, B. A., Stone, G. W., Wang, T. Y. Tags: Acute Coronary Syndromes, Coronary Artery Disease Coronary Heart Disease Source Type: research

Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes Coronary Heart Disease
BackgroundThe relationship between troponin level and outcomes among patients with non‐ST‐segment elevation ACS is established, but the relationship of troponin level with long‐term outcomes among medically managed non‐ST‐segment elevation ACS patients receiving contemporary antiplatelet therapy is inadequately defined.Methods and ResultsIn 6763 medically managed non‐ST‐segment elevation ACS patients randomized in TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) (prasugrel versus clopidogrel), we examined relationships between categories o...
Source: JAHA:Journal of the American Heart Association - April 11, 2017 Category: Cardiology Authors: Goldstein, S. A., Newby, L. K., Cyr, D. D., Neely, M., Luscher, T. F., Brown, E. B., White, H. D., Ohman, E. M., Roe, M. T., Hamm, C. W. Tags: Acute Coronary Syndromes Original Research Source Type: research

Clopidogrel Hypersensitivity: Overview of the Problem.
Abstract Clopidogrel is one of the most commonly prescribed drugs worldwide. It plays an essential therapeutic role in a variety of vascular conditions including acute coronary syndromes, ischemic heart disease treated with coronary stents, stroke, and peripheral vascular disease. Hypersensitivity reactions to clopidogrel are not uncommon and lead to its discontinuation in 1-2% of patients. Clopidogrel hypersensitivity is especially problematic in patients with newly implanted drug-eluting coronary stents. Premature discontinuation of dual antiplatelet therapy after recent coronary intervention is the most importa...
Source: Current Vascular Pharmacology - August 20, 2018 Category: Drugs & Pharmacology Authors: Savage MP, Fischman DL Tags: Curr Vasc Pharmacol Source Type: research

Did Generic Clopidogrel Commercialization Affect Trends of ER Consultations and Hospitalizations in the Population Treated with Clopidogrel?
ConclusionsThe population treated with  clopidogrel had similar rates of hospitalizations or ER consultations before and after generics commercialization. However, differences in rates of hospitalizations or ER consultations between generic and brand-name clopidogrel users may represent a drug safety signal which remains to be validated . Using a different study design, permitting adjustment for potential confounders, could be useful in this regard.
Source: Drugs and Aging - May 9, 2019 Category: Geriatrics Source Type: research

Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review
In conclusion, the evidence thus far has not been significant enough for the American College of Cardiology to recommend the incorporation of oral anticoagulants in the management of stable ischemic heart disease patients, in contrast to aspirin and clopidogrel. As the antithrombotic and antiischemic properties of these newer agents seem evident, so does their potential for increase in risk of bleeding events. Doctors have to individually tailor antithrombotic medication decisions based on the patient ’s risk-benefit profile.
Source: Current Cardiology Reports - May 17, 2019 Category: Cardiology Source Type: research

Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: Systematic Review of Current Literature
Conclusions: The use of DOACs is a reasonable alternative to vitamin-K antagonists in the management of LVT.
Source: American Journal of Therapeutics - November 1, 2020 Category: Drugs & Pharmacology Tags: Systematic Review and Clinical Guidelines Source Type: research

Antiplatelet agents and anticoagulants for hypertension
CONCLUSIONS: There is no evidence that antiplatelet therapy modifies mortality in patients with elevated BP for primary prevention. ASA reduced the risk of cardiovascular events and increased the risk of major bleeding events. Antiplatelet therapy with ASA probably reduces the risk of non-fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events compared to ASA in patients with elevated BP for secondary prevention. There is no evidence that warfarin modifies mortality in patients with elevated BP for secondary prevention. The benefits and harms of the newer dr...
Source: Cochrane Database of Systematic Reviews - July 28, 2022 Category: General Medicine Authors: Eduard Shantsila Monika Kozie ł-Siołkowska Gregory Yh Lip Source Type: research

Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
ConclusionsIn patients who receive clopidogrel after PCI, concomitant use of PPI seems to increase the risk of major cardiovascular events.
Source: Cardiovascular Drugs and Therapy - November 11, 2022 Category: Cardiology Source Type: research

Potentially Inappropriate Medication Use Among Older Patients with Diabetes in a Chinese Community
Conclusions Given the higher rate of PIM use among older adults with diabetes, strategies and interventions targeting this population are needed to minimize PIM use. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Experimental and Clinical Endocrinology and Diabetes - September 6, 2023 Category: Endocrinology Authors: Zhao, Xingxing Li, Lei Guo, Xiujun Wang, Jianqiang Yan, Yingying Le, Yunyi Tags: Article Source Type: research

Pages: 1  2  3  4